

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Abbosch, Chris	Invited Faculty	1. AstraZeneca 2. Bristol Myers Squibb 3. Roche Diagnostics, Novartis 4. University College London	1. Current AstraZeneca fellow, member of global study team managing MERMAID studies, speaker fees, advisory board 2. Previous speaker/travel fees 3. Previous speaker fees 4. Patents in MRD detect [Method of detecting tumour recurrence, methods for lung cancer detection]
Abed, Afaf	Abstract Presenter	Nothing to disclose	Nothing to disclose
Abou-Abdou, Somaya	Invited Faculty	Nothing to disclose	Nothing to disclose
Acharya, Rashmi	Abstract Presenter	Nothing to disclose	Nothing to disclose
Adjei, Alex	Invited Faculty	Nothing to disclose	Nothing to disclose
Adusumilli, Prasad	Invited Faculty Program Committee Member Abstract Grader	1. i) NCI - R01 CA236615-01, R01 CA 235667-01A1, R01 CA217169-01A1, R21 CA213139, T32, P30 CA008748, ii) DOD - BC132124, LC160212, CA170630, CA180889, CA200437 2. Baker Street Foundation, Batishwa Fellowship, Comedy vs Cancer Award, DallePezze Foundation, Derfner Foundation, Esophageal Education Research Foundation (ECEf), Experimental Therapeutics Center (MSK), Geoffrey Beene Foundation (MSK), Technology Development Fund (MSK) 3. Atara Biotherapeutics 4. BioArdis, Carisma Therapeutics, Imugene, ImmPACT Bio 5. Atara Biotherapeutics, Bayer, Takeda Therapeutics 6. Mesothelin CAR and PD1 DNR licensed to Atara Biotherapeutics 7. Mesothelin CAR, PD1DNR, CARs with new targets and costimulatory domain, Ex-vivo pleural effusion culture system (ePECS), Wireless pulse oximetry (Wipox) device, Detection of cancer cells by oncolytic virus	1. Federal grant support 2. Peer-reviewed grant support (foundations) 3. Research grant support 4. Scientific advisory board 5. Consultant 6. Licensing and Royalty 7. Patents (issued and applications)
Aerts, Joachim	Invited Faculty Program Committee Member Abstract Grader	1. Amphera, Erasmus MC 2. BMS, Roche, Amphera, Eli-Lilly, BIOCAD, MSD, Bayer 3. Allogenic tumor cell lysate, biomarker for immuno-oncology, combination immunotherapy in oncology	1. Stock or no stock options 2. Advisory board 3. Royalties/Intellectual property/Patent beneficiary
Afladhia, Hanna	Abstract Presenter	Nothing to disclose	Nothing to disclose
Aggarwal, Charu	Invited Faculty Program Committee Co	1. AZ, BluPrint, BMS, Celgene, Merck, Roche, Daichii-Sankyo 2. AZ, Merck, Novartis, Xencor	1. Advisory board 2. Clinical trial (to institution)
Agne, Julia	Abstract Presenter	Nothing to disclose	Nothing to disclose
Aguiar, Pedro	Invited Faculty	1. Boehringer Ingelheim 2. AstraZeneca	1. Speaker and Consultant Honorarium 2. Speaker Honorarium
Ahn, Bokyoung	Abstract Presenter	Nothing to disclose	Nothing to disclose
Ahn, Myung-Ju	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Aisner, Dara	Invited Faculty Program Committee Chair/ROC	1. Blueprint Medicine 2. Genentech	1. Consultant 2. Research funding from ineligible companies
Akbay, Esra	Abstract Grader	Nothing to disclose	Nothing to disclose
Alatorre, Jorge	Invited Faculty Program Committee Member Abstract Grader	1. MSD, ASTRA ZENECA, ROCHE, BMS, TAKEDA, NOVARTIS 2. MSD, BMS, ROCHE, ASTRA ZENECA,	1. Speakers Bureau 2. Advisory Board
Aldea, Mihaela	Abstract Grader	Nothing to disclose	Nothing to disclose
Alnajar, Ahmed	Abstract Presenter	Nothing to disclose	Nothing to disclose
Altan, Mehmet	Abstract Grader	1. Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab. 2. AstraZeneca (educational content development) 3. GlaxoSmithKline, Shattuck Lab	1. Research funding (to institution) 2. Speakers bureau 3. Advisory board
Altorki, Nasser	Invited Faculty Abstract Presenter	1. NCI Moonshoot Grant 1 UG3 CA244697-01, DoD LC200388 2. Johnson & Johnson, Lung Cancer Initiative, SUS Polyethnic-1000 Initiative New York Genome Center 3. AstraZeneca, Merck 4. Astrazeneca	1. Research grant 2. Contracted/support research 3. Investigator-initiated clinical trial 4. Advisory board
Anagnostou, Valsamo	Program Committee Member Abstract Presenter Abstract Grader Invited Faculty	1. Bristol Myers Squibb, AstraZeneca	1. Research funding from ineligible companies
Antonoff, Mara	Abstract Presenter	Nothing to disclose	Nothing to disclose
Aokage, Keiju	Invited Faculty Program Committee Member	1. TAIHO medical, Orympus medical 2. Johnson and Johnson, Astrazenaca, Chugai pharma, Ili Lilly	1. Consultant 2. Other: Honoraria
Araujo, Antonio	Peer Reviewers CME	Nothing to disclose	Nothing to disclose

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Arcila, Maria	Invited Faculty Program Committee Member Abstract Grader	1. Biocatis, Invivoscribe, Physician educationa resources, Peerview institute for medical education, clinical care options, RMEI medical education 2. Janssen Global Services, Bristol-Myers Squibb, AstraZeneca	1. Speaker 2. Consulting
Arenberg, Doug	Invited Faculty	Nothing to disclose	Nothing to disclose
Arrieta, Oscar	Abstract Presenter	1. Pfizer, AstraZeneca, Boehringer-Ingelheim, Roche 2. Pfizer, AstraZeneca, Boehringer-Ingelheim, Roche, Takeda, MSD 3. AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Merck 4. AstraZeneca, Boehringer-Ingelheim, Roche, Takeda, Lilly, Bristol Myers Squibb, MSD	1. Consultant 2. Advisory board 3. Research funding 4. Speaker's bureau
Asamura, Hisao	Invited Faculty Program Committee Member Abstract Grader	1. Johnson and Johnson, Medtronic 2. Medtronic, Taiho pharmaceutical, Johnson and Johnson, Lilly, Astellas, Ono pharmaceutical	1. Honorarium (lecture fee) 2. Research grant
Ashizawa, Kazuto	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ayık Türk, Merve	Abstract Presenter	Nothing to disclose	Nothing to disclose
Baas, Paul	Invited Faculty Program Committee Member Abstract Grader	1. BMS, MSD (research with MSD ended) 2. BMS, Beigene (finances paid to the hospital)	1. Research funding from ineligible companies 2. Advisory Board
Backhus, Leah	Invited Faculty	1. Johnson & Johnson	1. Advisory Board
Badiyan, Shahed	Abstract Grader	1. MEVION	1. Speakers bureau
Baird, Anne-Marie	Invited Faculty Program Committee Member Abstract Presenter Abstract Grader	1. Roche (Ireland) 2. I have been President of Lung Cancer Europe (LuCE) a non profit patient umbrella organisation since May 2020. LuCE has received support to undertake educational activities from the following companies: Amgen, AstraZeneca, Bayer, Blueprint Medicines, BMS, Boehringer Ingelheim, Genzyme Corporation, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Takeda; Janssen, Daiichi Sankyo (Honorarium).	1. Advisory board 2. Other: President, LuCE
Baldotto, Clarissa	Invited Faculty	1. MSD, Boehringer Ingelheim, Ethicon, Covidien, Chugai-pharm, Astellas Pharma, FUJIFILM Medical, Bristol-Myers Squibb 2. Teijin, Chugai-pharm, TAIHO, Boehringer Ingelheim, Lilly, ETHICON, Covidien	1. Honoraria (e.g. Lecture fees) 2. Research funding
Baldwin, David	Invited Faculty	1. MSD, BMS, Roche, AstraZeneca	1. Honorarium
Banerjee, Smita	Invited Faculty	Nothing to disclose	Nothing to disclose
Bar, Jair	Abstract Presenter	1. Bayer, BMS, Boheringer Ingelheim, Pfizer, Causalis 2. Astra Zeneca 3. Novartis, Takeda, Abbvie, MSD 4. Roche 5. ImmuneAI, OncoHost	1. Advisory board 2. Advisory board, Local and Country study PI 3. Advisory board, Insitutional study PI 4. Advisory board, Institutional study PI, Steering committee member 5. Research grant
Barbi, Joseph	Abstract Presenter	Nothing to disclose	Nothing to disclose
Barlesi, Fabrice	Program Committee Member Abstract Grader	1. Institutional financial interests: Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis and Takeda	1. Advisory Board
Basher, Fahmin	Abstract Presenter	Nothing to disclose	Nothing to disclose
Bastani, Mehrad	Abstract Presenter	Nothing to disclose	Nothing to disclose
Basu Roy, Upal	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Bazhenova, Lyudmila	Invited Faculty Program Committee Member Abstract Grader	1. Johnson and Johnson, Daichi Sankyo, Boehringer Ingelheim, BMS, Merck, Regeneron, Novartis 2. Epic Sciences 3. Beyondsping	1. Advisory board 2. Stock or stock options 3. Research funding from ineligible companies
Beane-Ebel, Jennifer	Invited Faculty Program Committee Member Abstract Grader	1. Janssen Pharmaceuticals 2. Veracyte	1. Research funding from ineligible companies 2. Royalties/Intellectual property/Patent beneficiary
Behera, Madhusmita	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Bell, Sigourney	Invited Faculty	Nothing to disclose	Nothing to disclose
Benitez, Jose Carlos	Abstract Presenter	Nothing to disclose	Nothing to disclose
Beqari, Jorind	Abstract Presenter	Nothing to disclose	Nothing to disclose

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Berezowska, Sabina	Invited Faculty Program Committee Member Abstract Grader	1. Eli Lilly (ended)	1. Advisory board
Berg, Christine	Abstract Presenter	Nothing to disclose	Nothing to disclose
Berger, Alice	Invited Faculty	Nothing to disclose	Nothing to disclose
Bernacki, Rachelle	Invited Faculty	Nothing to disclose	Nothing to disclose
Bertoglio, Pietro	Abstract Presenter	Nothing to disclose	Nothing to disclose
Bertolaccini, Luca	Abstract Presenter	Nothing to disclose	Nothing to disclose
Besse, Benjamin	Invited Faculty	Nothing to disclose	Nothing to disclose
Beasley, Mary Beth	Invited Faculty	Nothing to disclose	Nothing to disclose
Black, Kirsten	IASLC Staff	Nothing to disclose	Nothing to disclose
Blinman, Prunella	Program Committee Member Abstract Grader	1. Pfizer 2. MSD	1. Advisory Board 2. Consultant
Blum, Torsten Gerriet	Invited Faculty	Nothing to disclose	Nothing to disclose
Boehmer, Leigh	Abstract Presenter	1. Pfizer, Inc. (ended as of 6/1/21.)	1. Consultant
Boeri, Mattia	Abstract Grader	Nothing to disclose	Nothing to disclose
Bonanno, Laura	Abstract Presenter	1. Roche, Astra-Zeneca, BMS, MSD 2. Astra-Zeneca	1. Speakers bureau 2. Advisory board
Bradley, Jeff	Program Committee Member Abstract Grader	1. Varian, Inc, Genentech, Inc 2. Mevion Medical Systems, Inc	1. Consultant 2. Advisory Board
Brahmer, Julie	Invited Faculty	1. Amgen, BMS, Genentech, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Easi, AstraZeneca, Regeneron, Turning Point 2. Sanofi, GlaxoSmithKline, Janssen	1. Advisory board 2. Other: DSMB
Brunelli, Vanessa	Abstract Presenter Abstract Grader	Nothing to disclose	Nothing to disclose
Brustugun, Odd Terje	Peer Reviewers CME	1. AstraZeneca (funding to Institution) 2. MSD, AstraZeneca 3. Sanofi, AstraZeneca, Bayer, BoehringerIngelheim, Novartis, Roche	1. Research funding from ineligible companies (funding to institution) 2. Advisory board 3. Consultant
Bubendorf, Lukas	Invited Faculty Program Committee Member Abstract Grader	1. Amgen, Astra Zeneca, Janssen, Takeda 2. Systems Oncology 3. Roche, Novartis	1. Advisory board 2. Consultant 3. Stock or stock options
Bueno, Raphael	Invited Faculty	Nothing to disclose	Nothing to disclose
Bui, Alex	Invited Faculty	Nothing to disclose	Nothing to disclose
Bungaro, Maristella	Abstract Presenter	Nothing to disclose	Nothing to disclose
Burgess, Lisa	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Byers, Lauren	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, Gen Mab, Sierra Oncology 2. ToleroPharmaceuticals 3. PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals, Genentech and Debiopharm Group	1. Advisor/Consultant and Research Funding 2. Research funding from ineligible companies 3. Advisory Board
Calles, Antonio	Program Committee Member Abstract Grader	1. AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche, Lilly, Takeda, Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb 2. Merck Sharp & Dohme	1. Advisory Board 2. Research funding from ineligible companies
Calvo, Virginia	Abstract Presenter	1. Merck, Genetech/Roche, AstraZeneca, Bristol Myers-Squibb, Pfizer, Mirati, Lilly, Janssen, Blueprint, Novartis 2. AstraZeneca	1. Advisory board 2. IDMC
Camidge, D. Ross	Abstract Presenter Abstract Grader Program Committee Member	1. Kestrel, Nuvalent 2. Seattle Genetics, Takeda, Turning Point 3. Abbvie, Apollomics, AstraZenca, Elevation (Scientific Review Committee), AstraZeneca (Steering Committee), Daiichi-Sankyo (ILD adjudication committee)	1. Advisory Board 2. Consultant 3. Other
Campelo, Rosario Garcia	Invited Faculty	1. Takeda, AstraZeneca, Roche, Pfizer, BMS, Boehringer Ingelheim, Pfizer, Janssen, Eli Lilly	1. Other: Consulting/Advisory role
Canfell, Karen	Invited Faculty	Nothing to disclose	Nothing to disclose
Cantini, Luca	Abstract Presenter	Nothing to disclose	Nothing to disclose
Cappuzzo, Federico	Invited Faculty	1. Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, MSD, Novartis, Sanofi, Amgen	1. Fees for membership of an advisory board

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Carbone, David	Invited Faculty Abstract Presenter	1. AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Bristol Myers Squibb Japan, Curio Science, Daiichi Sankyo, Eli Lilly, EMD Serono, Flame Biosciences, G1 Therapeutics (Intellisphere), Geneplus, GlaxoSmithKline, Gloria Biosciences, Incyte, Inivata, Inovio Pharmaceutical, Janssen, Johnson & Johnson, Kyowa Hakko Kirin, Loxo, Merck, Merck KGaA, MSD, Nexus, Novartis, Novocure, Oncocyte, OncoHost, Pfizer, Piper Sandler, Roche/Genentech, Sanofi, and Takeda 2. James Cancer Centre of Ohio State University 3. AstraZeneca and Nexus Pharmaceutical 4. Bristol Myers Squibb	1. Advisory/ consulting fees 2. Employment 3. Honoraria 4. Research funding
Cardona Zorrilla, Andres	Invited Faculty Program Committee Member Abstract Grader	1. Foundation for Clinical and Applied Cancer Research INQBox 2. Roche, BI, Pfizer, Novartis, Celldex, Astra, Astrellas, Amgen, MSD, Merck Serono, Eisai, TEVA, Janssen, BioNTech, Amgen, Teva Pharma 3. Roche, BI, Pfizer, Novartis, Astra, Amgen, BMS, MSD, Eisai, Pfizer, Novartis, Merck, Serono 4. Roche, BI, Novartis, BMS, Abbie, Celldex, Idylla, Termo Fisher, Illumina, Amgen, Eli Lilly, Guardant Health, Roche Biocare 5. Roche, BI, Novartis, Foundation Medicine, Astra, QOF, Idylla, Roche Diagnostics, Amgen, Bayer, CCF, Idylla	1. Ownership Interest 2. Consultant/ Advisory Board 3. Honoraria from Speakers Bureau 4. Other Commercial Research Support 5. Research Grant
Cardone, Antonella	Invited Faculty	Nothing to disclose	Nothing to disclose
Cargill, Kasey	Abstract Grader	Nothing to disclose	Nothing to disclose
Cedres, Susana	Abstract Presenter	1. BMS, MSD, Boheringuer	1. Advisory board
Cedzynska, Magdalena	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Chaft, Jamie	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, Merck, Genentech, Guardant Helath, Janssen, Novartis, Regeneron/Sanofi, Flame Biosciences 2. AstraZeneca, Merck, Genentech, Flame Biosciences	1. Consultant 2. Contracted research support to institution
Chambers, Suzanne	Invited Faculty	1. Bayer, AbbVie	1. Speakers bureau
Champiat, Stephane	Invited Faculty	1. Alderaan Biotechnology, Amgen, AstraZeneca, Oncovita, Seagen, Ultrahuman 2. Amgen, AstraZeneca, BMS, Eisai, Janssen, MSD, Novartis and Roche 3. Abbvie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor 4. AstraZeneca, MSD, Roche	1. Advisory board 2. Speakers bureau 3. Other: Principal/sub-Investigator of Clinical Trials 4. Other: Travel and congress
Chan, Joseph	Abstract Presenter	Nothing to disclose	Nothing to disclose
Charalambous, Andreas	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Chauhan, Aman	Abstract Presenter	1. BMS, Clovis Oncology, TerSera, EMD Serono 2. Ipsen, Novartis, Lexicon	1. Research support 2. Advisory board

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Chen, Huanhuan	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Chen, Joyce	Invited Faculty	Nothing to disclose	Nothing to disclose
Chen, Kaishen	Invited Faculty	Nothing to disclose	Nothing to disclose
Chen, Yueqing	Abstract Presenter	Nothing to disclose	Nothing to disclose
Chiang, Anne	Invited Faculty	1. BMS, Astrazeneca 2. Astrazeneca, Flatiron, Jazz, Genentech, Regeneron, Catalyst	1. Research funding from ineligible companies 2. Advisory board
Cho, Byoung Chul	Invited Faculty Abstract Grader Program Committee Member	1. Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dival Pharma, MSD, Abbvie, Medpacto, GInnovation, Eli Lilly, Blueprint medicines, Interpark Bio Convergence Corp. CJ, Oscotec 2. Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines, CJ, Oscotec 3. TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp. 4. KANAPH Therapeutic Inc, Brigebio therapeutics, Cyrus therapeutics, Guardant Health 5. Interpark Bio Convergence Corp 6. Champions Oncology 7. DAAN Biotherapeutics	1. Research Funding 2. Consulting role 3. Stock Ownership 4. Scientific Advisory Board 5. Board of Directors 6. Royalty 7. Founder
Choy, Cheryl	ICS Staff	Nothing to disclose	Nothing to disclose
Choy, Hak	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Chun, Stephen	Invited Faculty	1. AstraZeneca, PLC, Norton Healthcare, Inc	1. Consultant
Ciupek, Andrew	Invited Faculty Program Committee Chair	1. Novartis, GRAIL 2. Astra Zeneca, Daiichi Sankyo, Pfizer, Novartis	1. Consultant 2. Advisory board
Cooper, Wendy	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Corrales, Luis	Invited Faculty Program Committee Chair Abstract Grader	1. Roche, Astra Zeneca, Pfizer, Novartis, MSD 2. Roche, Astra Zeneca, Pfizer, Novartis, MSD 3. Roche, Novartis, MSD 4. Roche, Novartis, Astra Zeneca	1. Consultant/ Advisory Board 2. Honoraria from Speakers Bureau 3. Other Commercial Research Support 4. Research Grant
Csaba, Degi	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Culligan, Melissa	Program Committee Chair Abstract Presenter Abstract Grader	Nothing to disclose	Nothing to disclose
Cummings, Michael	Invited Faculty Abstract Presenter	Nothing to disclose	Nothing to disclose
Cunha, Mateus	Abstract Presenter	Nothing to disclose	Nothing to disclose
Curioni, Alessandra	Invited Faculty	1. AstraZeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, Roche, Takeda	1. Advisory role
Dacic, Sanja	Invited Faculty Program Committee Member	1. Astra Zeneca 2. Takeda (ended), Janssen (ended)	1. Consultant 2. Advisory board
Daigneault, Jill	IASLC Staff	Nothing to disclose	Nothing to disclose
Daly, Megan	Invited Faculty	1. Genentech, Merck, EMD Serono (ended)	1. Research funding from ineligible companies
D'Amico, Thomas	Program Committee Member Abstract Grader	1. Scanlan Instruments	1. Consultant
Darlison, Liz	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Davies, Marianne	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Desai, Aakash	Abstract Presenter	Nothing to disclose	Nothing to disclose
Di Maio, Massimo	Invited Faculty	Nothing to disclose	Nothing to disclose
Dickson, Franco	Abstract Presenter	Nothing to disclose	Nothing to disclose
Diehn, Max	Invited Faculty Program Committee Chair Abstract Grader	1. CiberMed, Foresight Diagnostics 2. Roche 3. AstraZeneca, Roche, Genentech 4. Roche, Novartis, Gritstone Oncology, BioNTech 5. Varian Medical Systems, Illumina	1. Ownership or ownership interest 2. Royalties/Intellectual Property/Patent beneficiary 3. Advisory Board 4. Consultant 5. Research funding from ineligible companies
Dientsmann, Rodrigo	Invited Faculty	Nothing to disclose	Nothing to disclose
Dingemans, Anne-Marie	Invited Faculty Program Committee Member Abstract Grader	1. Roche, Boehringer Ingelheim, Amgen, Bayer, Pharmamar, Sanofi 2. Roche 3. Eli Lilly, Astra Zeneca, Ciesi, Pfizer, Takeda	1. Advisory Board 2. Steering Committee 3. Honorarium

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
		4. Jansen 5. Amgen	4. Honorarium (industry sponsored symposium) 5. Research support
Dive, Caroline	Program Committee Member Abstract Grader	1. AstraZeneca, Astex Pharmaceuticals, Biogen, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics Inc, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific, Neomed Therapeutics. 2. Biocartis, Merck, AstraZeneca.	1. Research funding from ineligible companies 2. Advisory Board
Dong, Song	Invited Faculty	Nothing to disclose	Nothing to disclose
Donington, Jessica	Invited Faculty Program Committee Chair/ROC Abstract Grader	1. AstraZeneca, BMS, Genentech	1. Speakers bureau
Doroshov, Deborah	Invited Faculty	1. MJH Life Sciences, Global Data, Dedham Group, Atheneum Partners (ended), Guidepoint Global Advisors (ended), Boston Healthcare Associates (ended)	1. Consultant
Dowlati, Afshin	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Drapkin, Benjamin	Invited Faculty	Nothing to disclose	Nothing to disclose
Dresler, Carolyn	Invited Faculty Program Committee/ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Drezner, Nicole	Invited Faculty	Nothing to disclose	Nothing to disclose
Drilon, Alex	Program Committee Member Abstract Grader	1. Roche, Bayer 2. Elevation Oncology, Liberum, Pfizer, EMD Serono, Repare Therapeutics, Novartis, Lilly Oncology, AstraZeneca, Monopteros Therapeutics	1. Speakers Bureau 2. Consultant
Duan, Jianchun	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Duarte, Brianda	IASLC Staff	Nothing to disclose	Nothing to disclose
Dubinet, Steven	Invited Faculty Program Committee Chair/ROC Abstract Grader	1. EarlyDiagnostics, Johnson & Johnson Lung Cancer Initiative, LungLife AI INC, T-Cure Bioscience INC 2. EarlyDiagnostics, LungLife AI INC	1. Advisory board 2. Stock or stock options
Duma, Narjust	Invited Faculty Abstract Grader Program Committee Member	Nothing to disclose	Nothing to disclose
Egwuenu, Caleb	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ejegi-Memeh, Stephanie	Abstract Grader	Nothing to disclose	Nothing to disclose
Elkins, Ivy	Invited Faculty Program Committee Member Abstract Presenter Abstract Grader	1. Boehringer Ingelheim, AstraZeneca, BMS, Blueprint Medicine, Sanofi Genzyme, J&J/Janssen, Bayer (ended)	1. Consultant
Eng, Lawson	Invited Faculty	Nothing to disclose	Nothing to disclose
Erhunmwunsee, Loretta	Invited Faculty Program Committee Chair/ROC	1. AstraZeneca Pharmaceuticals 2. AstraZeneca Pharmaceuticals	1. Research funding from ineligible companies 2. Advisory board
Evans, Bill	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Evison, Matt	Invited Faculty	Nothing to disclose	Nothing to disclose
Ezeife, Doreen	Abstract Presenter	1. Pfizer, BMS 2. Novartis	1. Horarium 2. Advisory board
Faccioli, Renata	Abstract Presenter	Nothing to disclose	Nothing to disclose
Faivre-Finn, Corinne	Invited Faculty Abstract Grader	1. AstraZeneca 2. Elekta, AstraZeneca	1. Advisory board 2. Research funding from ineligible companies
Fan, Li	Invited Faculty	Nothing to disclose	Nothing to disclose
Fan, Xinglong	Abstract Presenter	Nothing to disclose	Nothing to disclose
Fang, Wentao	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Fathi, Joelle	Invited Faculty Program Committee Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Feldman, Jill	Invited Faculty Abstract Grader Program Committee Co Chair	Nothing to disclose	Nothing to disclose
Felip, Enriquetta	Invited Faculty	1. BMS, Roche, MSD, Boehringer	1. Advisory board
Fenimore, Jackie	Abstract Presenter	The Global Lung Cancer Coalition (GLCC) receives funding for its work from a number of Sustaining Partners: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche and Takeda Oncology	

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Ferris, Andrea	Program Committee/ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Fidler, Mary Jo	Program Committee Member Abstract Grader	1. AstraZeneca, G1 Therapeutics 2. Jazz 3. Pfizer, biosesix, Pfizer, Rakeuten, Alkermes, Merck, AstraZeneca (ended with Pfizer)	1. Advisory Board 2. Consultant 3. Research funding from ineligible companies
Field, John	Invited Faculty Abstract Presenter	1. AstraZeneca 2. Epigenomics, NUCLEIX Ltd, AstraZeneca, iDNA 3. Janssen Research & Development LLC	1. Speaker bureau 2. Advisory board 3. Grant Support
Forde, Patrick	Program Committee Member Abstract Grader	1. AstraZeneca, BMS, Novartis, Corvus 2. Amgen, AstraZeneca, Daiichi, Novartis, Janssen 3. Polaris, Flame Therapeutics	1. Research funding from ineligible companies 2. Advisory Board 3. DSMB
Freeman-Daily, Janet	Program Committee Member Abstract Grader	1. Genentech 2. Genentech, Turning Point Therapeutics	1. Advisory Board 2. Others
Frowen, Jacqui	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ftanou, Maria	Invited Faculty Program Committee Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Gaafar, Rabab	Invited Faculty	Nothing to disclose	Nothing to disclose
Gadgeel, Shirish	Program Committee Member Abstract Presenter Abstract Grader	1. Merck, Genentech/Roche, Astra-Zeneca, Bristol Myers-Squibb, Pfizer, Mirati, Lilly, Janssen, Blueprint, Novartis 2. Astra-Zeneca	1. Advisory Board 2. IDMC
Galateau-Salle, Françoise	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Gandara, David	Invited Faculty	1. Amgen, AstraZeneca, Genentech, Roche-Genentech, Merck 2. AstraZeneca, Roche-Genentech, Guardant Health, Inivata, IO Biotech, Lilly, Merck, Novartis, Oncocyte 3. AstraZeneca, Roche-Genentech, Guardant Health, Inivata, IO Biotech, Lilly, Merck, Novartis, Oncocyte	1. Research funding from ineligible companies 2. Consultant 3. Advisory board
Gandhi, Leena	Invited Faculty	Nothing to disclose	Nothing to disclose
Ganti, Apar Kishor	Abstract Presenter CME Committee Chair	1. Merck, Apexigen (ended), Nektar, Top Alliance Biosciences, Iovance, Novartis, WindMil Therapeutics (ended) 2. Takeda 3. AstraZeneca, Mirati Therapeutics (ended), G1 Therapeutics (ended), Blueprint Medicines (ended), Cardinal Health (ended), Roche (ended) 4. Flagship Biosciences 5. YMabS Therapeutics (Ended - Apexigen, Mirati Therapeutics, G1 Therapeutics, Blueprint Medicines, Cardinal Health, Roche, WindMil Therapeutics)	1. Research funding from ineligible companies (All to institution) 2. Research funding from ineligible companies 3. Advisory board 4. Consultant 5. Other - DSMC Chair
Garassino, Marina	Invited Speaker Program Committee Co Chair Abstract Grader Abstract Presenter	1. AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati, Daiichi Sankyo, Regeneron 2. Eli Lilly, MSD, Pfizer (MISP), AstraZenecamm MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, Glaxo Smith Kline GSK, Specturm pharmaceuticals 3. AIRC, AIFA, Italian Moh, TRANSCAN	1. Personal financial interest 2. Institutional financial interests 3. Other- Research funding
Garcia-Roman, Silvia	Abstract Presenter	Nothing to disclose	Nothing to disclose
Garon, Edward	Abstract Presenter	1. ABL Bio, Boehringer Ingelheim, Bristol Myers Squibb, Dracen Pharmaceuticals, Eisai, EMD Serono, GSK, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio Therapeutics 2. AstraZeneca, Bristol Myers Squibb, Dynavax Technologies, EMD Serono, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis 3. Daiichi Sankyo, Inc.	1. Consulting or Advisory Role 2. Grant/Research Support 3. Honorarium
Garrido, Pilar	Invited Faculty	1. Abbvie, Amgen, AstraZeneca, Bayer, BMS, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Takeda 2. Bayer, AstraZeneca, Janssen, Novartis, Roche, Takeda	1. Advisory Board 2. Speakers Bureau
Gaspar, Laurie	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Gast, Kelly	Abstract Presenter	Nothing to disclose	Nothing to disclose

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Gauthier, Marie-Pier	Abstract Presenter	Nothing to disclose	Nothing to disclose
Gay, Carl	Invited Faculty	1. AstraZeneca, Jazz Pharmaceuticals 2. Kisoji Biotechnology, Open Health	1. Advisory Board 2. Consultant
Gelatti, Ana	Invited Faculty	Nothing to disclose	Nothing to disclose
Gentzler, Ryan	Abstract Grader	1. Mirati, Daiichi Sankyo, Jounce Therapeutics, Hellsinn, Takeda, BMS, Merck Pfizer 2. AstraZeneca, Blueprint Medicines, Daiichi Sankyo (All ended)	1. Research funding 2. Advisory board (all ended)
George, Julie	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ghiringhelli, Francois	Invited Faculty	1. Amgen, Roche, Servier 2. Roche, Merck Serono 3. Astra-Zeneca	1. Travel 2. Consulting 3. Research Grant
Gil Bazo, Ignacio	Abstract Grader	1. MSD, BMS, Eli Lilly, Amgen, AstraZeneca 2. MSD, BMS, Eli Lilly, AstraZeneca	1. Speakers Bureau 2. Advisory Board
Giorlando, Maria Aime	Abstract Grader	Nothing to disclose	Nothing to disclose
Girling, Benedict	Abstract Presenter	Nothing to disclose	Nothing to disclose
Girvalaki, Charis	Invited Faculty	Nothing to disclose	Nothing to disclose
Giuliani, Meredith	Invited Faculty	Nothing to disclose	Nothing to disclose
Goldberg, Sarah	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, Boehringer Ingelheim 2. AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Regeneron, Takeda, Janssen	1. Research funding from ineligible companies 2. Advisory board
Goldman, Jonathan	Peer Reviewers CME	1. AbbVie, Advaxis, Array/Pfizer, AstraZeneca, BMS, Eli Lilly, Genentech, Merck, Pfizer, Puma, Spectrum, Tesaro, Vaccinex 2. AbbVie, Astra Zeneca, BMS, Genentech, Janssen, Pfizer 3. Astra Zeneca	1. Research funding from ineligible companies 2. Advisory board 3. Others - Travel Support
Goldstein, Daniel	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Gomez, Jorge	Abstract Presenter	Nothing to disclose	Nothing to disclose
Gore, Elizabeth	Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Goss, Glenwood	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Goto, Yasushi	Invited Faculty Program Committee Member Abstract Grader	1. Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Glaxo Smith Kline, MSD, Guardant Health, Dai-ichi Sankyo, Kyorin, Chugai, Illumina 2. AstraZeneca, Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, MSD, Shionogi Pharma, Novartis 3. Abbvie, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, Dai-ichi Sankyo, Pfizer, Novartis, Kyorin, Chugai, Guardant Health, Daiichi-Sankyo	1. Consulting or advisory role 2. Speaker's bureau 3. Research funding (institution)
Gowda, Manoj	Abstract Grader	Nothing to disclose	Nothing to disclose
Goyvaerts, Cleo	Abstract Grader	Nothing to disclose	Nothing to disclose
Gray, Jhanelle	Invited Faculty Program Committee Chair /ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Gronberg, Bjorn	Invited Faculty	1. MSD, AstraZeneca, Pfizer, Takeda 2. Debiopharm, Janssen, Sanofi	1. Speakers bureau 2. Advisory board
Guckenberger, Matthias	Invited Faculty	1. Varian, Viewray, Astra Zeneca 2. Astra Zeneca	1. Research Support 2. Speaker Honoraria
Guerin, Maria	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Guo, Wei	Abstract Presenter	Nothing to disclose	Nothing to disclose
Gyawali, Bishal	Invited Faculty Program Committee Co Chair Abstract Grader	1. Vivio Healthcare	1. Other: Consulting fees
Han, Han	Abstract Presenter	Nothing to disclose	Nothing to disclose
Han, Yuchen	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Hanna, Gerry	Invited Faculty	1. AstraZeneca	1. Speakers Bureau
Hanna, Timothy	Invited Faculty	1. Roche	1. Research funding from ineligible companies
Hao, Desiree	Abstract Presenter	Nothing to disclose	Nothing to disclose
Harada, Ken	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Harpole, David	Conference Chair Invited Faculty Abstract Grader	1. Astra Zeneca Scientific Advisory Board and AEGEAN Steering Committee, Medtronic Scientific Advisory Board, Novartis Scientific Advisory Board	1. Advisory Board
Hasegawa, Kazuo	Invited Faculty	Nothing to disclose	Nothing to disclose
Hasegawa, Seiki	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Hatton, Matthew	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Hayashi, Hidetoshi	Invited Faculty Program Committee Chair Abstract Grader	1. AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Merck Biopharma Co., Ltd., MSD K.K., Novartis pharmaceuticals k.k, Ono Pharmaceutical Co. Ltd., and Pfizer Japan Inc. 2. AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi-Sankyo Cp.Ltd, Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Shanghai Haihe Biopharm, Janssen Pharmaceutical K.K. and Takeda Pharmaceutical Company Limited. 3. AstraZeneca K.K., Astellas Pharma Inc., MSD K.K., Ono Pharmaceutical Co.,Ltd., Nippon Boehringer Ingelheim Co.,Ltd., Novartis Pharma K.K., grants, Pfizer Japan Inc., Bristol Myers Squibb Company, Eli Lilly Japan K.K., Chugai Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Merck Serono Co., Ltd./ Merck Biopharma Co., Ltd., g, Takeda Pharmaceutical Co.,Ltd., Taiho Pharmaceutical Co.,Ltd., Symbio Pharmaceuticals Limited., AbbVie Inc, inVentiv Health Japan, ICON Japan K.K., GRITSONE ONCOLOGY.INC, PAREXEL International Corp., Kissei Pharmaceutical Co.,Ltd., EPS Corporation., Syneos Health., Pfizer R&D Japan G.K., A2 Healthcare Corp., Quintiles Inc. / IQVIA Services JAPAN K.K., EP-CRSU CO., LTD., Linical Co.,Ltd., Eisai Co., Ltd., CMIC Shift Zero K.K., Kyowa Hakko Kirin Co.,Ltd, Bayer Yakuhin, Ltd, EPS International Co.,Ltd, Otsuka Pharmaceutical Co., Ltd.	1. Speakers bureau 2. Advisory board 3. Research funding from ineligible companies
He, Jianxing	Abstract Presenter	Nothing to disclose	Nothing to disclose
Head, Lia	Abstract Presenter	Nothing to disclose	Nothing to disclose
Hendriks, Lizza	Program Committee Member Invited Faculty Abstract Grader	1. Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda 2. Boehringer Ingelheim, BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen 3. MSD 4. Roche Genentech 5. AstraZeneca 6. AstraZeneca 7. Roche Genentech 8. AstraZeneca, Novartis, BMS, MSD/Merck, TSK, Takeda, Blueprint, Roche, Janssen, Mirati	1. Research funding from ineligible companies 2. Advisory board 3. Speakers bureau 4. Other: travel/conference support 5. Other: mentorship program with KOL 6. Other: fees for webinars 7. Other: interview sessions 8. Other: local PI pharma study
Hennink, Merel	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Herth, Felix	Invited Faculty	1. Novartis, Bayer, Boehringer Ingelheim, AstraZeneca, Eli Lilly, GSK, C4 Therapeutics, Amgen 2. Merck Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda 3. Novartis, AstraZeneca, GlaxoSmithKline, Bayer, Pfizer, Amgen	1. Advisory role and consultant 2. Travel and honorarium 3. Research funding
Higgins, Kristin	Conference Co-Chair Invited Faculty Abstract Grader	Nothing to disclose	Nothing to disclose
Hijmering-Kappelle, Lucie	Abstract Presenter	Nothing to disclose	Nothing to disclose
Hirsch, Fred	Invited Faculty	1. Genentech/Roche, Bristol-Myers Squibb, AstraZeneca, Merck, Novartis, Daiichi-Sankyo, Amgen, OncoCyte, Eli Lilly/Loxo, Boehringer Ingelheim, Sanofi/Regeneron	1. Advisory board
Hollenbeck, Gina	Invited Faculty	1. Pfizer, Takeda 2. Pfizer	1. Advisory board 2. Consultant
Horinouchi, Hidehito	Peer Reviewers CME	1. AbbVie, MSD, Chugai/Roche, Daiichi-Sankyo, Jassen, and Genomic Health	1. Research funding from ineligible companies
Hui, Rina	Invited Faculty	1. AstraZeneca, BMS, Eisai, Eli Lilly, Merck, MSD, Novartis, Oncosec, Pfizer, Roche, Seagen 2. AstraZeneca, MSD, Novartis	1. Advisory board 2. Other: Speaker

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Huynh, Caroline	Abstract Presenter	Nothing to disclose	Nothing to disclose
Ichinose, Junji	Abstract Presenter	Nothing to disclose	Nothing to disclose
Ikeda, Norihiko	Program Committee Member Abstract Grader	1. Astra Zeneca, Chugai pharma, Pfizer, Taiho pharma, MSD, Boehringer Ingelheim, Eli Lilly, Ono pharma, Teijin, Nihon Mediphysics Bristol-Meyers, Olympus, Medtronic, Johnson & Johnson	1. Speakers Bureau
Ito, Kristin	IASLC Staff	Nothing to disclose	Nothing to disclose
Iyengar, Puneeth	Invited Faculty Abstract Grader Program Committee Member	1. AZ 2. Incyte, Pfizer 3. Volastra	1. Advisory board 2. Funding for research 3. Consultant
Jablons, David	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Jain, Deepali	Invited Faculty	Nothing to disclose	Nothing to disclose
Janne, Pasi	Program Committee Co Chair/ROC Abstract Presenter Abstract Grader	1. AstraZeneca, Boehringer Ingelheim, Pfizer, Chugai Pharmaceuticals, Daiichi Sankyo, Takeda Oncology, Syndax, Nuvalent, Bayer, Esai, Eli Lilly 2. Voronoi, Mirati Therapeutics, Transcenta, Silicon Therapeutics 3. AstraZeneca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim, Revolution Medicines	1. Consultant 2. Advisory Board 3. Research funding from ineligible companies
Jaradeh, Mark	Abstract Presenter	Nothing to disclose	Nothing to disclose
Jassem, Jacek	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Jebbink, Merel	Abstract Presenter	Nothing to disclose	Nothing to disclose
Jin, Yujuan	Abstract Presenter	Nothing to disclose	Nothing to disclose
Jiwani, Sabita	Invited Faculty	Nothing to disclose	Nothing to disclose
Johnson, Melissa	Invited Faculty Program Committee Co Chair Abstract Presenter Abstract Grader	1. AbbVie, Acerta, Adaptimmune, Apexigen, Array BioPharma, AstraZeneca, Atreca BeiGene, BerGenBio, Boehringer Ingelheim, Calithera Biosciences, Checkpoint Therapeutics, Corvus Pharmaceuticals, CytomX, Daiichi Sankyo, Dynavax, Lilly, EMD Serono, Genentech/Roche, Genmab, Genocera Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics, Immunocore, Incyte, Janssen, Jounce Therapeutics, Kadmon Pharmaceuticals, Loxo Oncology, Lycera, Merck, Mirati Therapeutics, Neovia Oncology, Novartis, OncoMed Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Sanofi, Seven and Eight Biopharmaceuticals, Shattuck Labs, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, University of Michigan, WindMIL, TCR2 Therapeutics, Arcus Biosciences, Ribon Therapeutics, Amgen, TMUNITY Therapeutics 2. AbbVie, Achilles Therapeutics, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, EMD Serono, Genentech / Roche, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Incyte, Janssen, Lilly, Loxo Oncology, Merck, Mirati Therapeutics, Novartis, Pfizer, Ribon Therapeutics, Sanofi, Association of Community Cancer Centers, WindMIL 3. AstraZeneca, Roche/Genentech, Merck, Sanofi, Pfizer, Abbvie, Incyte	1. Research funding (all to institution) 2. Consulting/Advisory role (self; all to institution) 3. Food/Beverage/Travel
Joubert, Phillipe	Program Committee Member Abstract Grader	1. AstraZeneca 2. Pfizer, AstraZeneca	1. Research funding from ineligible companies 2. Speakers Bureau
Judd, Julia	Abstract Presenter	Nothing to disclose	Nothing to disclose
Juergens, Rosalyn	Invited Faculty Program Committee Member/ROC Abstract Grader	1. Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Jazz Pharmaceuticals, Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi, Takeda 2. Amgen, Astellas, AstraZeneca, Bold Therapeutics, Bristol Myers Squibb, Debio Pharmaceuticals, Fusion Pharmaceuticals, MacroGenics, Merck Sharp and Dohme 3. Amgen, AstraZeneca, Bristol Myers Squibb, Jazz Pharmaceuticals, Merck Sharp and Dohme, Novartis, Takeda 4. Bristol Myers Squibb, Merck Sharp and Dohme, Pfizer	1. Advisory board 2. Contracted Research 3. Honoraria 4. Consultant
Jung, Hyun Ae	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kadara, Humam	Invited Faculty	1. MSD, Boehringer Ingelheim, Ethicon, Covidien, Chugai-pharm, Astellas Pharma, FUJIFILM Medical, Bristol-Myers Squibb	1. Honoraria (e.g. Lecture fees)

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
		2. Teijin, Chugai-pharm, TAIHO, Boehringer Ingelheim, Lilly, ETHICON, Covidien	2. Research funding
Kanakasetty, Govind Babu	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Kang, Jin	Abstract Grader Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Katayama, Ryohei	Program Committee Member Abstract Grader	1. Chugai, Takeda, Toppan Printing 2. Pfizer 3. Takeda, Deloitte (All - ended)	1. Research funding 2. Speaker bureau 3. Consultant (All - ended)
Kato, Terufumi	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, Merck KGA, MSD, Pfizer, Novartis, Daiichi-Sankyo, Eli Lilly 2. AstaraZeneca, Merck KGA, Daiichi Sankyo, Eli Lilly, Chugai, MSD, Pfizer, Novartis 3. AstraZeneca, Chugai, Eli Lilly, Abbvie, Pfizer, MSD, Merck KGA, Regeneron, Novartis, Amgen	1. Advisory board 2. Speakers bureau 3. Research funding from ineligible companies
Katsuya, Yuki	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Katz, Sharyn	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Kawasumi, Kenji	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kazerooni, Ella	Invited Faculty	Nothing to disclose	Nothing to disclose
Kehl, Kenneth	Abstract Presenter	1. Roche; IBM (ended)	1. Other - Speaking fees; honoraria
Kidane, Biniam	Invited Faculty	1. Astra Zeneca	1. Advisory board
Kim, Jae	Invited Faculty	1. Eli Lilly	1. Research funding from ineligible companies
Kim, Yeon Wook	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kim, Young-Tae	Invited Faculty Program Committee Member Abstract Grader	1. Johnson and Johnson (ended)	1. Advisory board
Kindler, Hedy	Invited Faculty	1. AstraZeneca, Blueprint, BMS, Deciphera, GSK, Harpoon, Inhibrx, Roche/Genentech, MacroGenics, Merck, Polaris, Seattle Genetics, Fibrogen 2. Ares Immunotherapy, AstraZeneca, Deciphera, Novocure 3. Seattle Genetics	1. Research funding from ineligible companies 2. Consultant 3. Advisory board
King, Jennifer	Invited Faculty Abstract Grader	1. Boehringer-Ingelheim 2. Guardant	1. Consultant 2. Advisory board
Kirschner, Michaela	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kiss, Nicole	Invited Faculty Program Committee Member	Nothing to disclose	Nothing to disclose
Kleczo, Emily	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kohonen-Corish, Maija	Abstract Grader	Nothing to disclose	Nothing to disclose
Kosari, Farhad	Abstract Presenter	Nothing to disclose	Nothing to disclose
Kumar, Arvind	Abstract Presenter	Nothing to disclose	Nothing to disclose
Labuc, Pippa	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Lai, Victoria	Invited Faculty Abstract Grader	1. AstraZeneca, G1 Therapeutics, Jazz Pharmaceuticals, Merck - Scientific Advisory Board, started June 2021	1. Advisory board
Lam, Vincent	Abstract Grader	1. BMS 2. SeaGen, BMS, AstraZeneca, Takeda (Takeda - Ended)	1. Research funding 2. Advisory board (Takeda - Ended)
Langer, Corey	Program Committee Member Abstract Grader	1. AZ, Genentech/Roche, Merck, Takeda, Advantagene, Trizell, Lilly 2. Merck, AZ, Genentech/Roche, Pfizer, Takeda, Gilead, Lilly	1. Research funding from ineligible companies 2. Advisory Board
Le, Brian	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Leal, Ticiana	Invited Faculty Program Committee Chair Abstract Grader	1. Astrazeneca, EMD Serono, Merck, Boehringer-Ingelheim, Bayer, Lilly, Janssen, Mirati (all ended) 2. Astrazeneca, Boehringer-Ingelheim, Blueprint, Jazz, Genentech (all ended)	1. Advisory board 2. Consultant
Lee, Jiyun	Abstract Presenter	Nothing to disclose	Nothing to disclose
Lee, Se-Hoon	Abstract Grader	1. MSD, Lunit 2. AstraZeneca/MedImmune, Roche, MSD, Bristol-Myers Squibb 3. AstraZeneca/MedImmune, Roche, Bristol-Myers Squibb	1. Research Funding 2. Speakers Bureau 3. Advisory Board
Lee, Seung Hyeun	Abstract Presenter	Nothing to disclose	Nothing to disclose
Lee, Tae Hoon	Abstract Presenter	Nothing to disclose	Nothing to disclose
Leigh, Lillian	Invited Faculty	1. Roche	1. Consultant
Leighl, Natasha	Invited Faculty Program Committee Member Abstract Grader	1. Amgen, Array Pharmaceuticals, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Guardant Helath, Lilly, MSD, Novartis, Pfizer, Roche, Takeda 2. Bristol Myers Squibb, MSD, Novartis, Takeda	1. Institutional Research Grant/Support 2. Honoraria (CME lectures)

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
		3. GSK, Helsinn, Mirati, Sanofi Genzyme 4. Teva-Oncotest	3. Advisor (compensated) 4. Travel (CME lectures)
Leone, Frank	Invited Faculty	Nothing to disclose	Nothing to disclose
Leung, Ann	Invited Faculty Program Committee Chair /ROC	Nothing to disclose	Nothing to disclose
Leung, Bonnie	Abstract Presenter	1. AstraZeneca, Takeda 2. Purdue	1. Honorarium 2. Advisory Board
Levy, Benjamin	Invited Faculty	1. AstraZeneca, Daiichi Sankyo, Janssen, BMS, Pfizer, Eli Lilly, Turning Point, Genentech, Roche 2. AstraZeneca, Daiichi Sankyo, Janssen, BMS, Pfizer, Eli Lilly, Turning Point, Genentech, Roche	1. Consulting/Advisory Board 2. Research support (Institution)
Lewis, Jennifer	Abstract Presenter	Nothing to disclose	Nothing to disclose
Li, Bob	Invited Faculty	1. NIH/NCI, Genentech Roche, Guardant, Henrui Therapeutics, Lilly, AstraZeneca, Daiichi Sankyo, GRAIL, MORE Health 2. Guardant, Henrui Therapeutics 3. MORE Health, Resolution Bioscience, Jiangsu Hengrui Medicine	1. Research funding from ineligible companies 2. Advisory Board 3. Travel
Li, Fasheng	Abstract Presenter	Nothing to disclose	Nothing to disclose
Li, Min	Abstract Presenter	Nothing to disclose	Nothing to disclose
Li, Shuai	Abstract Presenter	Nothing to disclose	Nothing to disclose
Li, Yan	Abstract Presenter	Nothing to disclose	Nothing to disclose
Lin, Chia-Chi	Abstract Grader	1. Bristol Myers Squibb, Eli Lilly, Novartis, Roche 2. Blueprint Medicines, Daiichi Sankyo, Novartis	1. Speakers bureau 2. Advisory board
Little, Jessica	Abstract Presenter	Nothing to disclose	Nothing to disclose
Liu, Jason	Abstract Presenter	Nothing to disclose	Nothing to disclose
Liu, Jiaqing	Abstract Presenter	Nothing to disclose	Nothing to disclose
Liu, Stephen	Program Committee Member Abstract Grader	1. Amgen, AstraZeneca, Beigene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, PharmaMar, Pfizer, Regeneron, Takeda 2. Inivata, Merck/MSD 3. Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Debiopharm, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics	1. Advisory Board 2. Consultant 3. Research funding from ineligible companies
Loong, Herbert	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Lopes, Gilberto	Invited Faculty Program Committee Member Abstract Grader	1. Blueprint, Pfizer, GSK, BMS, Merck, Bayer and others	1. Research funding from ineligible companies
Lopez-Rios, Fernando	Invited Faculty Program Committee Member Abstract Presenter	1. Thermo Fisher, Roche, Lilly 2. Janssen, BMS, Bayer, Roche, Bayer, Thermo Fisher, Pfizer 3. MSD, Lilly, AZ, Takeda, Roche, MSD	1. Research funding from ineligible companies 2. Advisory board 3. Speakers bureau
Lovly, Christine	Invited Faculty	1. Pfizer, Takeda, Amgen, Daiichi Sankyo, Janssen, Puma, Merck, AstraZeneca, Roche, Genentech, Syros	1. Advisory Board
Lu, Shun	Program Committee Member Abstract Presenter Abstract Grader	1. AstraZeneca, BMS, Hansoh, BaiGene, Hengrui, Hutchison MediPharma, Roche 2. AstraZeneca, Hansoh, Hengrui Therapeutics, Roche 3. AstraZeneca, Hutchison MediPharma, Roche, Boehringer Ingelheim, GenomiCare, InventisBio Co., Ltd., Menarini, Pfizer, priME Oncology, Simcere, Yuhan Corporaion, Zai Lab	1. Research support 2. Speaker fees 3. Advisor/Consultant
MacDonald, Fiona	Invited Faculty	Nothing to disclose	Nothing to disclose
Magalhães, Denise Simone	Abstract Presenter	Nothing to disclose	Nothing to disclose
Maher, Katie	IASLC Staff	Nothing to disclose	Nothing to disclose
Malec, Monica	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Malhotra, Jyoti	Abstract Grader	1. Bristol Myers Squibb, Celldex, Beyond Spring Pharmaceuticals 2. Astra Zeneca, Blueprnit Medicines	1. Research funding 2. Advisory board
Mallapelle, Umberto	Invited Faculty Program Committee Member Abstract Grader	1. Boehringer Ingelheim, Roche, MSD, AMGEN, Thermofisher Scientific, Merck Serono, Astrazeneca 2. Diaceutics, Eli Lilly 3. GSK	1. Speakers bureau 2. Consultant 3. Advisory board
Marmarelis, Melina	Abstract Grader	1. Gilead, Merck, Portola Pharmaceuticals, Bluebird Biosciences, Novartis, Pfizer (Ended - Pfizer) 2. Eli Lilly, Trizell, Merck 3. Novocure, Astra Zeneca	1. Stock or Stock Options 2. Research Funding from Ineligible Companies 3. Consultant

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Marom, Edith	Program Committee Member Abstract Grader	1. Boehringer Ingelheim (GOT PAID AND ENDED)	1. Other - Paid Lecture
Marques, Edouard	Abstract Presenter	Nothing to disclose	Nothing to disclose
Marston, Celia	Invited Faculty	Nothing to disclose	Nothing to disclose
Martin, Claudio	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Martin, Linda	Invited Faculty	1. Astra Zeneca, On Target Laboratories 2. Pacira Pharmaceuticals	1. Consultant 2. Advisory board
Martin, Megan	IASLC Staff	Nothing to disclose	Nothing to disclose
Mas, Luis	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Mascarenhas, Eldsamira	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Mathias, Clarissa	Invited Faculty	Nothing to disclose	Nothing to disclose
Matsumura, Yuki	Abstract Presenter	Nothing to disclose	Nothing to disclose
Mayfield, Bill	Invited Faculty	Nothing to disclose	Nothing to disclose
Mazzilli, Sara	Abstract Grader	1. BU (Funding to the institution)	1. Research funding
McLaughlin-Barrett, Sara	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
McWilliams, Annette	Invited Faculty Program Committee Member Abstract Grader	1. Olympus 2. Roche	1. Travel/accomodation costs to attend interventional pulmonology research workshops 2. Travel/accomodation costs to attend Oncology workshop as invited speaker
Meador, Catherine	Abstract Presenter	Nothing to disclose	Nothing to disclose
Merchant, Zoe	Invited Faculty	Nothing to disclose	Nothing to disclose
Mesko, Dave	IASLC Staff	Nothing to disclose	Nothing to disclose
Mitchell, Paul	Invited Faculty	1. AstraZeneca, Roche, Boehringer-Ingelheim, BMS, MSD, Amgen, Puma Biotechnology, Specialised Therapeutics, Novartis 2. Roche, AstraZeneca, MSD 3. BMS, AstraZeneca	1. Advisory boards 2. Honoraria 3. Research funding
Mitsudomi, Tetsuya	Reviewer, Invited Faculty	1. MSD, Taiho, Chugai, Eli-Lilly, Ono 2. AstraZeneca, Boehringer Ingelheim, Novartis, MSD, BMS, Ono, Chugai, Merck Biopharma, Takeda, Pfizer, Eli-Lilly 3. AstraZeneca, Amgen, Janssen pharma, MSD, Puma Biotech	1. Research funding from ineligible companies 2. Speakers bureau 3. Advisory board
Miura, Satoru	Abstract Presenter	1. Boehringer Ingelheim Inc., MSD Inc., Elli Lilly Japan, Ono Pharma Inc, Chugai Pharm Inc.	1. Speaker bureau
Moghanaki, Drew	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Mohindra, Pranshu	Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Molasiotis, Alex	Invited Faculty	Nothing to disclose	Nothing to disclose
Moor, Rebecca	Abstract Grader	1. Astra Zeneca (PI on clinical trial with funding awarded to insitution) 2. Astra Zeneca, Roche, BMS, MSD	1. Research funding 2. Other - Educational meeting speaker and attendee, travel costs
Moore, Amy	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Moore, Sara	Abstract Presenter	Nothing to disclose	Nothing to disclose
Mou, Benjamin	Abstract Presenter	1. Astra Zeneca	1. Honorarium
Mountzios, Giannis	Invited Faculty	1. AstraZeneca Greece, Roche Hellas, BMS Greece, Novartis Hellas, Takeda Greece, Pfizer Greece, Sanofi, Amgen Hellas 2. AstraZeneca Greece, Roche Hellas, BMS Greece, Novartis Hellas, Amgen Hellas 3. AstraZeneca Greece, Roche Hellas, BMS Greece, Novartis Hellas, Sanofi, Amgen Hellas	1. Advisory/Consultancy fees 2. Travel and accomodation fees 3. PI in sponsored clinical trials in the last 5 years
Moylan, Anne	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Mulimba, Ashlee	Invited Faculty	Nothing to disclose	Nothing to disclose
Munoz Schuffenegger, Pablo	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Muthusamy, Bharathi	Abstract Presenter	Nothing to disclose	Nothing to disclose
Myers, Renelle	Abstract Presenter	Nothing to disclose	Nothing to disclose
Nadal, Ernest	Abstract Presenter	1. Roche, Bristol Myers Squibb, Merck Serono, Pfizer 2. Roche, Bristol Myers Squibb, Pfizer, AstraZeneca, Amgen, Lilly, Bayer, Takeda, Boehringer Ingelheim 3. Roche, Bristol Myers Squibb, Pfizer, AstraZeneca, Amgen, Lilly, Bayer, Takeda, Boehringer-Ingelheim	1. Research Support 2. Speaker Bureau 3. Honoraria

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Nagasaka, Misako	Program Committee Member Abstract Grader	1. AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, JNJ and Pfizer 2. Blueprint Medicine 3. An Heart Therapeutics 4. Caris Life Sciences	1. Advisory Board 2. Speakers Bureau 3. Travel Support 4. Consultant
Naidoo, Jaruska	Abstract Grader	1. Merck, Astrazeneca 2. Merck, Astrazeneca, Bristol Myers Squibb, Pfizer, Takeda, Roche/Genentech	1. Research funding 2. Advisory board
Negrao, Marcelo	Abstract Presenter	1. Mirati, Novartis, Checkmate (ended), Ziopharm, AstraZeneca, Pfizer 2. Mirati 3. Mirati	1. Research funding from ineligible companies (Checkmate - ended) 2. Advisory board 3. Consultant
Nguyen, Sang	Abstract Presenter	Nothing to disclose	Nothing to disclose
Ni, Jianjiao	Abstract Presenter	Nothing to disclose	Nothing to disclose
Nie, Wei	Abstract Presenter	Nothing to disclose	Nothing to disclose
Nishino, Mizuki	Invited Faculty Program Committee Member	1. AstraZeneca, Daiichi Sankyo 2. AstraZeneca, Daiichi Sankyo, Canon Medical Systems	1. Consultant 2. Research grant to the institution
Novello, Silvia	Invited Faculty	1. AZ, Beigene, Takeda, Pfizer, Roche, Novartis, MSD, BI, AMG, Eli Lilly 2. AZ, Sanofi, Takeda, AMG, Eli Lilly, Roche, Pfizer	1. Speakers bureau 2. Advisory board
Nowak, Anna	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Obeng, Rebecca	Abstract Presenter	Nothing to disclose	Nothing to disclose
Oezkan, Filiz	Abstract Presenter	1. Decibio 2. Genentech/Roche	1. Consultant 2. Salary Support (active through 11/2020)
Okumura, Meinoshin	Invited Faculty	1. Alexion Japan	1. Other: Chairing a sponsored seminar in a domestic conference in Japan
Ollila, Hely	Abstract Presenter	Nothing to disclose	Nothing to disclose
Opitz, Isabelle	Invited Faculty Program Committee Member Abstract Grader	1. Medtronic, Roche 2. MSD, AstraZeneca 3. Roche, AstraZeneca	1. Research funding from ineligible companies 2. Advisory board 3. Speaker's Bureau
Osarogiagbon, Raymond	Invited Faculty Program Committee Member Abstract Presenter Abstract Grader	1. Oncobox Devices, Inc 2. Eli Lilly, Gilead Sciences, Pfizer 3. Biodesix 4. AstraZeneca, Triptych Healthcare Partners	1. Ownership or Ownership Interest 2. Stock or Stock options 3. Speakers Bureau 4. Consultant
Oser, Matthew	Abstract Grader	Nothing to disclose	Nothing to disclose
Ostroff, Jamie	Invited Faculty	Nothing to disclose	Nothing to disclose
Ou, Sai-Hong	Abstract Presenter	1. Pfizer, Astra Zeneca, Takeda, Roche/Genentech, Daiichi Sankyo, Janseen/JNJ 2. Turning Point Therapeutics, Elevation Oncology	1. Consultant 2. Stock or stock options
Oudkerk, Matthijs	Invited Faculty	1. KWF Kankerbestrijding 2. RvvZ 3. Siemens Germany and Netherlands 4. KNAW, NOW 5. Institute for Diagnostic Accuracy	1. Grants Zorg Onderzoek Nederland-Medische Wetenschappen 2. Stichting Centraal Fonds 3. Research Sponsors 4. Grants from ERC 5. Ministry of Science and Technology China
Owen, Dwight	Abstract Grader	1. BMS, Merck, Palobiofarma, Genentech, Onc.AI (all to institution)	1. Research fundings
Owonikoko, Taofeek	Invited Faculty Program Committee Member Abstract Grader	1. Novartis, Lilly, Sandoz, Abbvie, Eisai, G1 Therapeutics Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, XCover, Bayer, Heron Pharmaceutical, ARMO BioSciences, Merck, Bayer, Jazz, Zentalis, Ipsen 2. Novartis; Astellas Pharma, Bayer, StemCentRx, Regeneron, AstraZeneca, G1 Therapeutics, Bristol-Myers, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck, Mersana, Turning Point, Oncorus, Ipsen, Eisai, Roche/Genentech, 3. Cambium Oncology	1. Advisory board 2. Research funding from ineligible companies 3. Stock/ownership/Co-founder
Oyola, Sonia	Invited Faculty	Nothing to disclose	Nothing to disclose
Park, Keunchil	Invited Faculty Abstract Grader	1. Astra Zeneca, MSD 2. Astra Zeneca, Boehringer Ingelheim, Daiichi Sankyo, Merck KGaA 3. AMGEN, Astra Zeneca, BluePrint, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, Janssen Research & Development, Merck KGaA, MSD, Ono Pharmaceutical, Puma Biotechnology, Roche, Takeda 4. BeiGene, Incyte	1. Research funding from ineligible companies 2. Speakers bureau 3. Advisory board 4. Other (Data Monitoring Committee;)

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Pasquinelli, Mary	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Pass, Harvey	Invited Faculty Program Committee Member Abstract Grader	1. Genentech 2. Genentech, Research to Practice, Physicians Education Research, OncLive 3. Genentech, Novartis 4. Jones and Bartlett 5. Micronoma, Celsius, Owkin	1. Consultant 2. Speaker's bureau 3. Advisory board 4. Royalties 5. Contracted/Support research grant
Pastorino, Ugo	Invited Faculty	Nothing to disclose	Nothing to disclose
Patel, Jyoti	Invited Faculty Program Committee Member Abstract Grader Peer Reviewers CME	1. AstraZeneca, Takeda	1. Advisory board
Patel, Yogita S.	Abstract Presenter	Nothing to disclose	Nothing to disclose
Patella, Miriam	Abstract Presenter	Nothing to disclose	Nothing to disclose
Patil, Tejas	Abstract Grader	1. Pfizer, Turning Point Pharmaceuticals, Sanofi 2. Astrazeneca, Janssen, Guardant Health	1. Advisory board 2. Consultant
Patz Jr, Edward	Program Committee Member	1. Grid Therapeutics 2. Astra Zeneca (ONCOCYTE)	1. Ownership/Ownership Interest 2. Advisory Board
Pavlakis, Nick	Invited Faculty CME Monitor and Peer Reviewer	1. AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Merck KGA, Merck Sharp and Dohme, Pfizer, Roche, Takeda 2. AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Merck KGA, Merck Sharp and Dohme, Pfizer, Roche, Takeda, Ipsen 3. Bayer, Pfizer, Roche	1. Advisory Board 2. Honoraria 3. Research Funding to Institution
Paz-Ares, Luis	Abstract Presenter	1. Amgen, AZ, Bayer, GSK, Ipsen, Janssen, Lilly, Merck Serono, Mirati, MSD, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro 2. Altum sequencing 3. Alkermes, Amgen, AstraZeneca, BMS, Daiichi Sankyo, IO Biotech, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro	1. Advisory Board 2. Member of board of director 3. Coordinating PI, Institutional, Financial Interest
Peddle-McIntyre, Carolyn	Invited Faculty	Nothing to disclose	Nothing to disclose
Peled, Nir	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, FoundationMedicine, Gaudant360, Merck, MSD, Novartis, NovellusDx, Pfizer, Roche, Takeda	1. Research funding from ineligible companies
Pellini, Bruna	Invited Faculty Abstract Grader	1. BMS 2. BioAscend, OncLive (ended) 3. Astrazeneca (ended) 4. Guidepoint	1. Research funding from ineligible companies 2. Speakers bureau 3. Advisory board 4. Consultant
Pentz, Rebecca	Invited Faculty	Nothing to disclose	Nothing to disclose
Peters, Matthew	Abstract Presenter	Nothing to disclose	Nothing to disclose
Peters, Solange	Invited Faculty	1. AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, IQVIA, Incyte, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, PhosplatinTherapeutics, PER, Pfizer, PRIME, Regeneron, Roche/Genentech, RTP, Sanofi, Seattle Genetics, Takeda 2. AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, Takeda 3. (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Bodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, PhosplatinTherapeutics, Roche/Genentech	1. Consultation/Advisory Role 2. Talk in a company's organized public events 3. Receipt of grants/research support

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Pierce, Lori	Invited Faculty	1. PFS Genomics 2. Exact Sciences 3. a. UpToDate; b. Blue Cross Blue Shield of Michigan	1. Ownership or Ownership Interest 2. Consultant (non-compensated consultant) 3. Other: a. Editor Reviewer b. Salary Support as MROQC Coordinating Center Leadership
Pilotto, Sara	Invited Faculty	1. Astrazeneca, BMS 2. Astrazeneca, BMS, Roche, Merck&Co 3. Astrazeneca, BMS, Roche, Merck&Co, Amgen, Novartis, Boehringer Ingelheim	1. Research funding from ineligible companies 2. Speakers bureau 3. Consultant
Piotrowska, Zosia	Program Committee Member Abstract Grader	1. Takeda 2. Takeda, Novartis, Spectrum, AstraZeneca, Tesaro, Cullinan, Daiichi Sankyo, Abbvie	1. Advisory Board 2. Research funding from ineligible companies
Planchard, David	Invited Faculty	1. AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung 2. AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung 3. AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo 4. AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer	1. Consulting, advisory role or lectures 2. Honoraria 3. Clinical Trials Research 4. Travel, Accomodations, Expenses
Plank, April	Abstract Presenter	Nothing to disclose	Nothing to disclose
Platek, Debbie	IASLC Consultant	Nothing to disclose	Nothing to disclose
Poirier, John	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Politi, Katerina	Invited Faculty Program Committee Member Abstract Grader	1. Halda (ended) 2. AstraZeneca, Roche/Genentech, Boehringer Ingelheim 3. MSKCC/MolecularMD	1. Consultant 2. Research funding from ineligible companies 3. Royalties/Intellectual property/Patent beneficiary
Popat, Sanjay	Invited Faculty Program Committee Member Abstract Grader	1. Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Roche, Pfizer, Novartis, Xcovery, GSK, BMS, Incyte, Daiichi Sankyo, Janssen, Boehringer Ingelheim, Takeda, Eli Lilly, Seattle Genetics, Turning Point Therapeutics, MSD, Merck Serono, Guardant Health 2. Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Roche, Pfizer, Novartis, Xcovery, GSK, BMS, Incyte, Daiichi Sankyo, Janssen, Boehringer-Ingelheim, Takeda, Eli Lilly, Seattle Genetics, Turning Point Therapeutics, MSD, Merck Serono, Guardant Health	1. Consultancy 2. Honorarium
Provencio, Mariano	Abstract Presenter	1. Universidad Autonoma de Madrid, Chair of Medical Oncology Department at Puerta de Hierro Hospital 2. AstraZeneca, Roche, BMS, Boehringer-Ingelheim 3. AstraZeneca, BMS, Boehringer-Ingelheim, Celgene, MSD, Roche, Takeda, Thermo-Fisher	1. Employment 2. Research Grants 3. Consultant
Puri, Sonam	Invited Faculty Program Committee Member Abstract Presenter	1. G1 therapeutics 2. AstraZeneca	1. Advisory board 2. Consultant (BOTH ENDED)
Qin, Zhen	Abstract Presenter	Nothing to disclose	Nothing to disclose
Quintanal-Villalonga, Alvaro	Abstract Presenter	1. AstraZeneca 2. Filed patent application	1. Honorarium 2. Methods for predicting and treating chemoresistance in small cell lung cancer patients
Quist, Morten	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Raez, Luis	Invited Faculty Program Committee Chair Abstract Grader	1. Genentech, merck, lilly, loxo, syndax, nanth health, pfizer, novartis, astra zeneca, janssen	1. Research funding from ineligible companies
Ramalingam, Suresh	Invited Faculty	1. Amgen, AstraZeneca, BMS, Merck, Genmab, Eisai, Glaxo Smithkline 2. Amgen, AstraZeneca, BMS, Merck, Fenmab, Eisai, Glaxo Smithkline, Takeda, Advaxis	1. Advisory board meeting 2. Research support to institution
Ray, Meredith	Abstract Presenter	1. National Institutes of Health	1. Research funding from ineligible companies
Raz, Dan	Invited Faculty	Nothing to disclose	Nothing to disclose
Reck, Martin	Program Committee Member Abstract Presenter	1. AstraZeneca, BMS, Boehringer-Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Samsung	1. Speakers Bureau

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
	Abstract Grader	2. Amgen, AstraZeneca, BMS, Boehringer-Ingelheim, Lilly, Celgene, Merck, MSD, Novartis, Pfizer, Roche, Samsung, Mirati 3. BMS	2. Advisory Board 3. Research funding from ineligible companies
Reckamp, Karen	Invited Faculty Program Committee Member Abstract Grader	1. Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, EMD Serono, Genentech, GSK, Guardant, Janssen, Lilly, Loxo, Mirati, Seattle Genetics, Takeda 2. AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol Myers Squibb, Calithera, Daiichi Sankyo, Elevation Oncology, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Seattle Genetics, Takeda, Xcovery, Zeno	1. Consulting/advisory fees 2. Research funding to the institution
Redman, Mary	Invited Faculty Program Committee Chair/ROC Abstract Grader	1. Merck (ended) 2. AstraZeneca ENDED	1. Consultant 2. Advisory Board
Reguart, Noemi	Invited Faculty	Nothing to disclose	Nothing to disclose
Remon, Jordi	Invited Faculty Program Committee Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Ren, Shengxiang	Invited Faculty Program Committee Member Abstract Presenter Peer Reviewers CME	1. Boehringer Ingelheim, Lilly, MSD, Roche, Hengrui, Junshi, BeiGene, Innovent, Takeda, Genecast 2. Roche, MSD, Boehringer Ingelheim, Hengrui 3. Hengrui	1. Speakers bureau 2. Advisory board 3. Consultant
Ricciuti, Biagio	Abstract Grader	Nothing to disclose	Nothing to disclose
Richeimer, Kristin	IASLC Staff	Nothing to disclose	Nothing to disclose
Rigney, Maureen	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Robinson, Andrew	Invited Faculty	1. Pfizer, Merck, AstraZeneca, BMS 2. Merck, Astrazeneca, BMS 3. Merck	1. Research funding 2. Advisory role 3. Honoraria
Rodin, Gary	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Rodriguez, Estelamari	Abstract Presenter	1. AstraZeneca 2. AstraZeneca 3. OnLive, Research to Practice, Targeted Oncology	1. Advisory board 2. Consultant 3. Speaker's Bureau
Rolfo, Christian	Invited Faculty Program Committee Member Abstract Grader	1. Deputy chair Educational Committee IALSC - Vice President ISLB (International Society of Liquid Biopsy) - Educational Chair: OLA Oncology Latin American Association Scientific Committee Member at ESO (European School of Oncology) 2. Research Collaboration: GuardantHealth 3. Speaker: MSD (ended), Roche, Astra Zeneca (ended), Advisory board: Inivata (ended), ArcherDx (ended), MD Serono, Novartis, Boston Pharmaceuticals 4. Research support: Biomark	1. Advisory Board 2. Non-financial interest 3. Personal financial interest 4. Institutional financial interest
Romero, Atocha	Abstract Presenter	1. Boehringer-Ingelheim	1. Consultant
Ronden, Merle	Abstract Presenter	Nothing to disclose	Nothing to disclose
Rothschild, Sacha	Abstract Presenter	Nothing to disclose	Nothing to disclose
Rotow, Julia	Invited Faculty	1. AbbVie, AstraZeneca, Lilly, Gritstone Oncology, Regeneron, Sanofi, Genzyme 2. Janssen, Chaitai Tianqing, Merck, Pfizer, Regeneron, Sanofi Genzyme, Takeda	1. Consulting 2. Honorarium
Rudin, Charles	Invited Faculty	1. Amgen, Astra Zeneca, Epizyme, Genentech/Roche, Ipsen, Jazz, Lilly, and Syros 2. Bridge Medicines, Earli, and Harpoon Therapeutics	1. Consultant 2. Advisory board
Ruiz Mendoza, Rossana	Abstract Grader	Nothing to disclose	Nothing to disclose
Rusch, Valerie	Invited Faculty	1. Genelux Inc, Genentech 2. Intuitive Surgical	1. Research funding from ineligible companies 2. Travel reimbursement
Russo, Alessandro	Abstract Grader	1. AstraZeneca 2. AstraZeneca, MSD 3. AstraZeneca	1. Speakers Bureau 2. Advisory Board 3. Consultant
Rzyman, Witold	Program Committee Member Abstract Grader	1. Medtronic (ENDED)	1. Advisory Board
Sabari, Josh	Invited Faculty	1. AstraZeneca, Genentech, Janssen, Pfizer, Regeneron, Sanofi Genzyme, Takeda 2. AstraZeneca, Genentech, Janssen, Navire	1. Advisory Board 2. Consultant
Sacher, Adrian	Invited Faculty Abstract Grader	1. Genentech-Roche, BMS, AstraZeneca, Amgen, Merck, RAIN Therapeutics, Spectrum, GSK, Iovance, Pfizer, CRISPR Therapeutics	1. Research funding from ineligible companies

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
		2. Genentech-Roche, BMS, AstraZeneca, Amgen, Merck, Iovance, Galvanize Therapeutics	2. Advisory Board
Saez, Daniel	Abstract Presenter	1. Novartis, Genzyme-Sanofi, AstraZeneca, Takeda 2. Roche-Genentech	1. Advisory board 2. Consultant
Saji, Hisashi	Invited Faculty	1. MSD, Boehringer Ingelheim, Ethicon, Covidien, Chugai-pharm, Astellas Pharma, FUJIFILM Medical, Bristol-Myers Squibb 2. Teijin, Chugai-pharm, TAIHO, Boehringer Ingelheim, Lilly, ETHICON, Covidien	1. Honoraria (e.g. Lecture fees) 2. Research funding
Sakai, Shuji	Invited Faculty	Nothing to disclose	Nothing to disclose
Sales dos Santos, Ricardo	Invited Faculty	Nothing disclose	Nothing disclose
Samson, Pamela	Invited Faculty	Nothing disclose	Nothing disclose
Samuelson, Catherine	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sanborn, Rachel	Program Committee Member Abstract Grader	1. Merck, AstraZeneca (Investigator-Initiated Trials), BMS, MedImmune (Institution Research Funding) 2. AstraZeneca, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Genentech/Roche, Janssen Oncology, Lilly 3. Macrogenics, AstraZeneca 4. Amgen: Honoraria for educational presentations AstraZeneca: Panel expert, Symposium presenter, Travel support	1. Research funding from ineligible companies 2. Advisory Board 3. Consultant 4. Other
Sands, Jacob	Abstract Grader Program Committee Member	Nothing to disclose	Nothing to disclose
Sarbay, Ismail	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sato, Takashi	Abstract Presenter	1. Chugai Pharmaceutical, Bristol Myers Squibb, Boehringer Ingelheim	1. Speakers bureau
Sauter, Jennifer	Invited Faculty	Nothing disclose	Nothing disclose
Scagliotti, Giorgio	Reviewer, Invited Faculty	Lilly, Roche, Pfizer, Astrazeneca, Novartis, MSD, Takeda	Consultant
Schabath, Matthew	Invited Faculty	Nothing disclose	Nothing disclose
Schalper, Kurt	Invited Faculty	1. Clinica Alemana de Santiago, PeerView, Moderna Therapeutics, Shattuck Labs, Pierre-Fabre, AstraZeneca, EMD Serono, Takeda, Torque Therapeutics, Bristol Myers Squibb, Agenus, Takeda, Merck 2. Navigate Biopharma, Tesaro/GSK, Moderna Therapeutics, Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol Myers Squibb, AstraZeneca, Ribon Therapeutics and Eli Lilly	1. Speaker, Consultant, Advisory Board Member 2. Research Funding
Scherpereel, Arnaud	Invited Faculty	1. i) AS is an investigator in phases I, II & III clinical trials sponsored by AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Epizyme, Lilly, MSD, Roche... with no personal payment, all honoraria being perceived by my Institution (CHU de Lille, Clinical Research Center, France), ii) Research grants from BMS, Roche to AS institution 2. Astra-Zeneca, BMS, Boehringer-Ingelheim, MSD, Roche 3. Astra-Zeneca, Roche, MSD, BMS	1. Grants/research support 2. Honoraria for participation to scientific or advisory Boards 3. invitation at some international oncology meetings (AACR, ASCO, WCLC)
Schmid, Sabine	Abstract Presenter	1. BMS, AstraZeneca 2. BMS, Boehringer Ingelheim, MSD 3. Boehringer Ingelheim, MSD, Takeda	1. Research Grant (Institutional) 2. Advisory Board (Institutional) 3. Travel support
Schoenherr, Grit	ICS Staff	Nothing to disclose	Nothing to disclose
Segal, Leopoldo	Invited Faculty	1. Sanofi	1. Consulting
Sellmer, Laura	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sen, Triparna	Invited Faculty Abstract Grader	Nothing to disclose	Nothing to disclose
Senan, Suresh	Invited Faculty Program Committee Member Abstract Grader	1. AstraZeneca, ViewRay Inc, Varian Medical Systems, MSD, BeiGene 2. AstraZeneca, BMS 3. ViewRay Inc, Varian Medical Systems	1. Advisory Board 2. Institutional Research Support 3. Departmental Research Support
Sepesi, Boris	Abstract Grader	Nothing to disclose	Nothing to disclose
Sequist, Lecia	Invited Faculty	1. AstraZeneca, Janssen, Genentech 2. AstraZeneca, Novartis, Boehringer Ingelheim, Genentech	1. Advisory Board 2. Contracted/support research grant
Shankar, Abhishek	Invited Faculty	Nothing to disclose	Nothing to disclose
Shen, Colette	Abstract Presenter	1. Nanobiotix 2. Nanobiotix	1. Consulting or Advisory Role 2. Travel, Accommodations, Expenses
Shen, Yi-Luen	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sholl, Lynette	Invited Faculty Program Committee Co Chair Abstract Grader	1. Moderna 2. Genentech 3. Genentech, GV20 Therapeutics	1. Stock or stock options 2. Research funding from ineligible companies 3. Consultant
Sihoe, Alan	Program Committee Member	1. Medela AG	1. Advisory Board

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
	Abstract Grader	2. Nestle	2. Other - Honorarium received
Silva, Mario	Invited Faculty Abstract Grader	Nothing to disclose	Nothing to disclose
Silvestri, Gerard	Program Committee Co Chair Abstract Grader	1. Auris Medical, Biodesix, Exact Sciences, Oncocyte, Olympus, PCORI, Veran medical, NIH, NCI, RO1, Aries pharmaceutical, Nucleix, SEER, American Cancer Society 2. Astrazeneca 3. Auris Medical, Biodesix, Olympus, Aries pharmaceutical, Nucleix, Astrazeneca	1. Research funding from ineligible companies 2. Advisory Board 3. Consultant
Simon, George	Program Committee Member Abstract Grader	1. AstraZeneca, Boeringer Ingelheim, Takeda 2. G1Therapeutics	1. Advisory Board 2. Research funding from ineligible companies
Sirohi, Bhawna	Invited Faculty	Nothing to disclose	Nothing to disclose
Sit, Christina	Invited Faculty Abstract Presenter	Nothing to disclose	Nothing to disclose
Sivasubramian, Vanathi	Abstract Grader	Nothing to disclose	Nothing to disclose
Skoulidis, Ferdinandos	Abstract Presenter	1. Moderna, BioNTech 2. Amgen, Merck, Novartis 3. Tango Therapeutics 4. RV Mais Promocao Eventos LTDS 5. Pfizer 6. AstraZeneca	1. Stock or stock options 2. Research funding from ineligible companies 3. Other -Travel 4. Other - Fees for lecture 5. Other - Study chair funds to institution 6. Other - Food and beverage
Smeltzer, Matt	Program Committee Member Abstract Grader Abstract Presenter	Nothing to disclose	Nothing to disclose
Smith, Kellie	Abstract Grader	Nothing to disclose	Nothing to disclose
Smyth, Robert	Abstract Grader	Nothing to disclose	Nothing to disclose
Soo, Ross	Program Committee Member Abstract Grader	1. Amgen, Astra-Zeneca, Bayer, BMS, Boehringer-Ingelheim, Lily, Merck, Novartis, Pfizer, Roche, Taiho, Takeda, Yuhan 2. Astra-Zeneca, Boehringer-Ingelheim	1. Advisory Board 2. Research Grant
Soon, Yu Yang	Abstract Grader	Nothing to disclose	Nothing to disclose
Spakowicz, Daniel	Abstract Grader	Nothing to disclose	Nothing to disclose
Spigel, David	Program Committee Member Abstract Grader	1. Aeglea Biotherapies, Astellas, AstraZeneca, BIND Therapeutics, Bristol-Myers Squibb, Celgene, Celldex, Clovis, Daiichi Sankyo, Eisai, Lilly, EMD Serono, G1 Therapeutics, Roche/Genentech, GlaxoSmithKline, GRAIL, ImClone Systems, ImmunoGen, Ipsen, Janssen, MedImmune, Merck, Molecular Partners, Nektar, Neon, Novartis, Takeda, Tesaro, Transgene, UT Southwestern, Agios, Cytair Therapeutics, and Apollomics 2. Amgen, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Curio Science, Dracen Pharmaceuticals, EMD Serono, Evelo Biosciences, Exelixis, GlaxoSmithKline, Iksuda Therapeutics, Intellisphere, Illumina, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati, Molecular Templates, Nektar Therapeutics, Novartis, Novocure, Pfizer, Pharma Mar, Puma Biotechnology, Roche/Genentech, Sanofi-Aventis, Seattle Genetics, Takeda, TRIPTYCH Health Partners, TRM Oncology, Williams and Connolly LLP, and Regeneron Pharmaceuticals	1. Research funding from ineligible companies-(ALL PAYMENTS MADE TO INSTITUTION) 2. Consultant-(ALL PAYMENTS MADE TO INSTITUTION)
Spira, Alexander	Abstract Presenter	1. Array BioPharma, Incyte, Amgen, Novartis, AstraZeneca/MedImmune, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Merck, Bristol-Myers Squibb 2. Lilly 3. CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol-Myers Squibb, Bayer 4. Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, LAM Therapeutics, Trovogene, Takeda, MacroGenics, CytomX Therapeutics, LAM Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone Oncology, Plexxikon, Amgen, Daiichi Sankyo, ADC therapeutics, Janssen Oncology, Mirati Therapeutics, Rubius	1. Consultant 2. Ownership or Stock interest 3. Honoraria 4. Contracted/Support Research Grant (Institution)
Steliga, Matthew	Invited Faculty Program Committee Member/ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Stensgaard, Jeanette	IASLC Staff	Nothing to disclose	Nothing to disclose

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Stiles, Brendan	Invited Faculty	1. AstraZeneca, Pfizer 2. AstraZeneca, Pfizer, Genentech, BMS, Gala Therapeutics, Flame Biosciences 3. Lung Cancer Research Foundation	1. Consultant 2. Advisory Board 3. Board Chair
Stinchcombe, Tom	Conference Co-Chair Invited Faculty Abstract Grader	1. Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron 2. Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, Regeneron (institution)	1. Advisory Board (ended) 2. Research funding from ineligible companies
Stone, Emily	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Studts, Jamie	Invited Faculty	1. AstraZeneca 2. J&J	1. Advisory Board 2. Consultant
Suarez Saiz, Fernando	Abstract Presenter Peer Reviewers CME	Nothing to disclose	Nothing to disclose
Subbiah, Vivek	Abstract Presenter	1. GlaxoSmithKline, Novartis, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg, Bayer, Incyte, Fujifilm, Pharmamar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Multivir, Blueprint Medicines, LOXO, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Turning Point Therapeutics 2. MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED Therapeutics 3. PharmaMar, Bayer, Novartis, Helsinn Therapeutics	1. Research funding from ineligible companies 2. Consultant 3. Other - Travel Accommodations, Expenses
Suciu, Aissa	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sun, Daqiang	Abstract Presenter	Nothing to disclose	Nothing to disclose
Sutherland, Kate	Invited Faculty Program Committee Member	1. AGIOS Pharmaceuticals 2. CYGNAL Therapeutics	1. Research funding from ineligible companies 2. Speakers Bureau
Swisher, Stephen	Invited Faculty Program Committee Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Szmytke, Ewelina	Invited Faculty	Nothing to disclose	Nothing to disclose
Tabuchi, Takahiro	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Tachihara, Motoko	Abstract Grader	1. AstraZeneca K. K 2. AstraZeneca K.K, Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan K.K, MSD K.K, Ono Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd 3. Eli Lilly Japan K. K	1. Research funding from ineligible companies 2. Speakers bureau 3. Advisory board
Tahir, Bilal	Abstract Presenter	Nothing to disclose	Nothing to disclose
Takamori, Shinkichi	Abstract Presenter	1. Boehringer Ingelheim, Merck 2. Boehringer Ingelheim 3. Guardant Health	1. Travel Fee 2. Honoraria 3. Advisory Board
Tammemagi, Martin	Abstract Presenter	1. Johnson & Johnson/Jassen, Medial EarlySign, Nucleix, bioAffinity Technologies, AstraZeneca	1. Consulting
Tan, Aaron	Abstract Presenter Abstract Grader	1. Amgen	1. Advisory Board
Tan, Daniel	Invited Faculty Peer Reviewers CME	1. Novartis, Bayer, Boehringer Ingelheim, AstraZeneca, Eli Lilly, GSK, C4 Therapeutics, Amgen 2. Merck Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda 3. Novartis, AstraZeneca, GlaxoSmithKline, Bayer, Pfizer, Amgen	1. Advisory role and consultant 2. Travel and honorarium 3. Research funding
Tanizaki, Junko	Abstract Grader	1. AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Taiho Pharmaceutical Co. Ltd. K.	1. Speakers Bureau
Taube, Janis	Invited Faculty	1. Bristol Myers Squibb, Compugen, Merck, Astra Zeneca, Akoya Biosciences 2. Akoya Biosciences 3. Bristol Myers Squibb, Akoya Biosciences	1. Advisory Board 2. Stock or stock options 3. Research funding from ineligible companies
Taylor, Bethany	Abstract Grader	Nothing to disclose	Nothing to disclose
Terra, Ricardo	Abstract Presenter	1. Medtronic 2. Intuitive Surgical	1. Speaker 2. Speaker and Proctor
Thomas, Anish	Invited Faculty	1. AstraZeneca, EMD Serono, Prolynx, Tarveda	1. Research funding from ineligible companies
Thompson, Jeffrey	Program Committee Member Abstract Presenter Abstract Grader	1. AstraZeneca	1. Advisory Board

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Togashi, Yosuke	Program Committee Member Abstract Grader	1. Ono Pharmaceuticals, BMS, KOTAI Biotechnologies, Daiichi Sankyo	1. Research funding from ineligible companies
Tomar, Vivek	Invited Faculty	Nothing to disclose	Nothing to disclose
Tong, Betty	Invited Faculty Program Committee Chair Abstract Grader	1. Medtronic Inc (no activities for -12 months)	1. Consultant
Trama, Annalisa	Invited Faculty	Nothing to disclose	Nothing to disclose
Treasure, Tom	Invited Faculty	Nothing to disclose	Nothing to disclose
Truong, Mylene	Program Committee Member/ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Tsao, Anne	Invited Faculty Program Committee Co Chair Abstract Presenter Abstract Grader	1. BMS, Eli Lilly, Genentech, Roche, Novartis, Ariad, EMD Serono, Merck, Seattle Genetics, Astra-Zeneca, Boehringer-Ingelheim, Sellas Life Science, Daiichi Sankyo, Takeda 2. Eli Lilly, Millenium, Polaris, Genentech, Merck, Boehringer-Ingelheim, BMS, Ariad, Epizyme, Seattle Genetics	1. Advisory Boards 2. Research Grants
Tsay, Jun-Chieh	Abstract Grader	Nothing to disclose	Nothing to disclose
Tsutani, Yasuhiro	Abstract Presenter	1. AstraZeneca, CareNet, Chugai, Covidien, Johnson and Johnson, MiRTel, Ono, Taiho 2. Advisory Board	1. Honorarium 2. Advisory Board
Turner, Michelle	Invited Faculty Program Committee Member Abstract Grader	1. Merck, AstraZeneca, Bristol Myers Squibb 2. Pfizer, Merck, AstraZeneca, Bristol Myers Squibb 3. Merck	1. Speakers bureau
Ubillos, Luis	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ueki, Kazuhito	Abstract Presenter	Nothing to disclose	Nothing to disclose
Ugalde, Paula	Invited Faculty	Nothing to disclose	Nothing to disclose
Valencia, Karmele	Abstract Grader	Nothing to disclose	Nothing to disclose
Vallejos Sologuren, Carlos	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
van der Wel, J.W.T.	Abstract Presenter	1. AstraZeneca	1. OSIRIS funding
van Meerbeeck, Jan	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Van Schil, Paul	Invited Faculty	Nothing to disclose	Nothing to disclose
Vansteenkiste, Johan	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Variotto, John	Program Committee Member Abstract Grader	1. Astra Zeneca, Novocure 2. Medtronic	1. Advisory Board 2. Consultant
Velcheti, Vamsidhar	Program Committee Member Abstract Grader	1. BMS, Astrazeneca, Foundation Medicine, Merck, EMD Sereno, Novartis	1. Consultant
Vellanki, Paz	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Ventura, Luigi	Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Veronesi, Giulia	Invited Faculty	1. Medtronic 2. Ab Medica 3. Johnson & Johnson 4. NCI, AIRC, LILT, FUV, Ministry of Health, Transcan, Intuitive	1. Speakers' Bureau 2. Proctoring 3. Honoraria 4. Competitive grants and research grants
Viola, Lucia	Invited Faculty	Nothing to disclose	Nothing to disclose
Vitek, Jennifer	IASLC Staff	Nothing to disclose	Nothing to disclose
Wakelee, Heather	Invited Faculty	1. Advisory board participation (compensated): Janssen (April 2019), Mirati (ongoing), Daiichi Sankyo (Sept 2019), Helsinn (ongoing) Advisory board (NOT compensated): Merck, Genentech/Roche, Cellworks 2. ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, Novartis, Pfizer, Pharmacyclics, Xcovery	1. Advisory board 2. Research funding from ineligible companies
Wang, Huijuan	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wang, Jie	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wang, Xiaofei	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wang, Xuequan	Abstract Presenter	Nothing to disclose	Nothing to disclose
Warren, Graham	Invited Faculty Program Committee Member/ROC Abstract Grader	Nothing to disclose	Nothing to disclose
Watanabe, Atsushi	Program Committee Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Wauters, Els	Invited Faculty	1. AstraZeneca	1. Research Grant

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
		2. BMS, MSD	2. Consultant
West, Howard	Invited Faculty Abstract Presenter	1. AstraZeneca, EQRx, Genentech/Roche, Merck, Mirati, Regeneron 2. AstraZeneca, EQRx, Genentech/Roche, Merck, Mirati, Regeneron 3. AstraZeneca, Merck	1. Advisory Board 2. Consultant 3. Speaker
Westergaard, Sarah	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wong, S.K	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wong, Sharlene	ICS Staff	Nothing to disclose	Nothing to disclose
Woodard, TaCharra	Invited Faculty	Nothing to disclose	Nothing to disclose
Wozniak, Antoinette	Peer Reviewers CME	1. Eli Lilly, Epizyme, Glaxo Smith Kline, Janssen, Novocure, Regenron 2. BeyondSpring, Odonate	1. Consultant 2. Other - DSMB
Wu, Kan	Abstract Presenter	Nothing to disclose	Nothing to disclose
Wu, Nan	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Wu, Yi-Long	Program Committee Member Abstract Grader	1. AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Hengrui, MSD, Pfizer, Roche, Sanofi 2. AstraZeneca, MSD, Hengrui, Takeda	1. Speakers Bureau 2. Consultant
Wynes, Murry	IASLC Staff	Nothing to disclose	Nothing to disclose
Xie, Hui	Invited Faculty	Nothing to disclose	Nothing to disclose
Yamaoka, Satoko Kono	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Yan, Shi	Abstract Grader	Nothing to disclose	Nothing to disclose
Yanagawa, Jane	Abstract Grader	Nothing to disclose	Nothing to disclose
Yang, Grace	Invited Faculty Program Committee Co Chair Abstract Grader	Nothing to disclose	Nothing to disclose
Yang, Li	Abstract Presenter	Nothing to disclose	Nothing to disclose
Yang, Pan Chyr	Invited Faculty	1. AstraZeneca, Boehringer Ingelheim, Pfizer, MSD, Eli Lilly, Roche, Merck, GSK, ONO Pharma 2. OBI Pharma, CHO Pharma, Onenessbio, DELTA Electronics	1. Honoraria 2. Advisory Board
Yano, Seiji	Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Yatabe, Yasushi	Program Committee Member Abstract Grader	1. MSD, Chugai-pharma, AstraZeneca, Pfizer, Roche/Ventana, Agilent/Dako, Thermo Fisher Science, ArcherDx, Novartis, Elli-Lily 2. MSD, Chugai-pharma, AstraZeneca, Novartis, Amgen, ArcherDx, Takeda, Daiichi-Sankyo, Janssen Pharma 3. ArcherDx, Chugai-pharma	1. Speakers Bureau 2. Advisory Board 3. Research funding from ineligible companies
Yegya-Raman, Nikhil	Abstract Presenter	Nothing to disclose	Nothing to disclose
Yin, Fang-Fang	Invited Faculty	1. Varian Medical Systems	1. Research funding from ineligible companies
Yip, Rowena	Abstract Presenter	Nothing to disclose	Nothing to disclose
Yoshida, Yukihiko	Abstract Presenter	Nothing to disclose	Nothing to disclose
Yoshino, Ichiro	Invited Faculty	1. AstraZeneca 2. Daiichisannkyo, Covidien, Intuitive Surgical, Taiho, MSD 3. Boehringer Ingelheim, Pfizer, Chugai, Taiho	1. Advisory board 2. Speakers bureau 3. Research funding from ineligible companies
Yoshiyasu, Nobuyuki	Abstract Presenter	Nothing to disclose	Nothing to disclose
Yu, Helena	Invited Faculty	1. AstraZeneca, Daiichi Sankyo, Janssen and Blueprint Medicine	1. Consultant
Zaini, Jamal	Abstract Grader	Nothing to disclose	Nothing to disclose
Zatarain Barron, Zyanza Lucia	Invited Faculty Program Committee Member Abstract Grader	Nothing to disclose	Nothing to disclose
Zhang, Andrew	Abstract Presenter	Nothing to disclose	Nothing to disclose
Zhang, Hua	Abstract Grader	Nothing to disclose	Nothing to disclose
Zhang, Li	Program Committee Member Abstract Presenter Abstract Grader	1. AstraZeneca, Amgen, BeiGene	1. Research grant
Zhang, Shirong	Abstract Presenter	Nothing to disclose	Nothing to disclose
Zhang, Wencai	Abstract Grader	Nothing to disclose	Nothing to disclose
Zheng, Mei-Mei	Abstract Presenter	Nothing to disclose	Nothing to disclose
Zhou, Caicun	Invited Faculty	1. Amoy Diagnostics, Boehringer Ingelheim, Cstone Pharmaceuticals, Eli Lilly China, Hengrui Medicine, Innovent Biologics, Luye Pharma, MSD, Quilu Pharmaceuticals, Roche, Sanofi, TopAlliance Biosciences 2. Hengrui Medicine, Innovent Biologics, Quilu Pharmaceuticals, TopAlliance Biosciences	1. Honorarium 2. Advisor

WCLC 2021 - Financial Disclosures

All relevant financial relationships have been mitigated.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(ies)	Nature of Financial Relationship(s)
Zhou, Qing	Invited Faculty Abstract Presenter	1. AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, Sanofi	1. Honoraria
Zhuo, Minglei	Abstract Grader	Nothing to disclose	Nothing to disclose
Zugazagoitia, Jon	Abstract Grader	1. Astra Zeneca 2. Roche, BMS, Astra Zeneca, NanoString 3. Novartis 4. NanoString	1. Research funding 2. Speakers Bureau 3. Advisory Board 4. Consultant